Discontinuation for adverse events or death related to adverse events in all patients and according to age
| . | All patients (n = 102) . | Patients age < 70 (n = 76) . | Patients age ≥ 70 (n = 26) . |
|---|---|---|---|
| Discontinuation for AEs or death related to AEs | 30 (29%) | 20 (26%) | 10 (38%) |
| AEs | 22 (22%) | 17 (22%) | 5 (19%) |
| Death related to AEs | 8 (8%) | 3 (5%)* | 5 (19%)* |
| . | All patients (n = 102) . | Patients age < 70 (n = 76) . | Patients age ≥ 70 (n = 26) . |
|---|---|---|---|
| Discontinuation for AEs or death related to AEs | 30 (29%) | 20 (26%) | 10 (38%) |
| AEs | 22 (22%) | 17 (22%) | 5 (19%) |
| Death related to AEs | 8 (8%) | 3 (5%)* | 5 (19%)* |
P value (Fisher exact test .024).